News summary: Judge halts Royalty Pharma Elan bid

News summary: Judge temporarily halts Royalty Pharma's latest bid for Irish drugmaker Elan

Associated Press

COURT STEPS IN: Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the Irish drugmaker.

THE BACKGROUND: Royalty made an offer to buy Elan last month for $12.50 per share, or about $7.5 billion. It made the offer on the condition that shareholders reject an Elan push to refocus its business after selling its interest in the multiple sclerosis treatment Tysabri.

ELAN'S VIEW: Elan has said the Royalty offer, which is scheduled to expire Thursday, undervalues Elan.

Sorry you didn't like this comment. Please provide a reason below.

Are you sure?
Rating failed. Try again.
Request failed. Try again.
We will promote constructive and witty comments to the top, so everyone sees them!
Sorry, we can’t load comments right now. Try again.

    Recommended for You